C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma…
Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms…
Multiple Star Models Lead the Way, AVATR Shines with “New Luxury” at 2025 Munich Auto Show (IAA)
MUNICH, Sept. 10, 2025 /PRNewswire/ -- AVATR made a high-profile appearance at…
TCL Secures Multiple Honors at IFA 2025 with Cutting-edge Smart-Living Solutions
BERLIN, Sept. 10, 2025 /PRNewswire/ -- TCL, a global leader in consumer…
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the…
Hunan TV Show Singer 2025 Draws Performers from Multiple Countries
CHANGSHA, China, Aug. 4, 2025 /PRNewswire/ -- Hunan TV's Mango TV program…
China Southern Power Grid Showcases Multiple AI Achievements at 2025 World Artificial Intelligence Conference
SHANGHAI, July 30, 2025 /PRNewswire/ -- From July 26 to 28, the 2025…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older…
Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly…
